ProCE Banner Activity

AGAVE-201 Response Analysis: Axatilimab for Patients With Chronic GVHD

Conference Coverage
Slideset

In the phase II AGAVE-201 trial in patients with chronic graft-vs-host-disease, axatilimab 0.3 mg/kg every 2 weeks demonstrated timely response and symptom improvement in the first 6 cycles of treatment, as presented at ASH 2024.

Released: December 09, 2024

Expiration: December 08, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation